Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
about
Recent Advances in Lentiviral Vaccines for HIV-1 InfectionA novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunitysiRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.mRNA-based dendritic cell vaccines.Potential approaches for more successful dendritic cell-based immunotherapy.Lentiviral vectors in cancer immunotherapy.New challenges in therapeutic vaccines against HIV infection.Novel immunotherapies for the treatment of melanoma.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence.Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis.PD1 signal transduction pathways in T cells.Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy.Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection.Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex™ platform.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in and Evaluation of Antitumor Activity In Vivo
P2860
Q26742169-B419DF36-88E4-47E6-9D0B-A6F98E4F9918Q33710008-C755712B-609C-4F59-9DB2-3086F9B470F6Q34654430-78DF0D50-9310-4FE4-ABC3-4DD58A1F6D23Q35224581-9E61D7C9-3793-4A5E-87A4-2999BD0ABD12Q35546869-7A81359A-F294-4F48-9B30-3BF07BC7FA2FQ36326288-EF13DE23-81CC-498B-A52A-F15A3BE5241EQ36512076-7B852B99-13C6-4413-A789-B9C890008589Q36656025-69B6E8D8-2ED6-4240-9104-EC355157B95AQ37277855-5E1CD12B-8908-4B4F-8339-73E482F484ACQ38246769-F8682662-C102-4EFC-BB00-A1031207CE4FQ38305650-157EBA8A-9C4F-44ED-A47D-056E7F39BFF3Q38389312-17DD705D-DC48-466F-AE57-2EBC39FFD3C4Q38692205-B69879D6-4B71-43E3-89FA-6D04E9915897Q38824190-0F6247A6-B2F6-4BE5-BE41-77B199A8D7CBQ38836740-E0A8ACB3-520C-43C1-967F-3617B4442B9EQ39401740-719752AC-FFEE-4FF1-A111-5538D5E2F58EQ39413389-838431DA-5747-4D06-84FC-A327FDCF164DQ40062424-2B9819D1-FB8A-491D-ADAE-CD2B3DE85112Q41636546-AE66F38D-6CE9-407B-82AA-3536ACECE73DQ46588562-B2D2BEAC-81DA-4C5A-926B-7FA4457AB6B2Q46694980-023AB7B1-A71F-4760-BE31-5357C3628A7AQ50531820-68FA61C7-3220-4547-991E-06A53D52E181Q51322748-1A11FE34-C175-4667-B64E-B15EB465623AQ55174561-0787C07E-85E1-458B-8398-EE7C4E77DE56Q55348052-3614EEE0-D9E3-4E20-BAC8-09206367A209Q55442759-8101EF85-1B6D-4072-9596-1E0D068094FDQ59138239-62760ABA-C99A-4614-973B-E44600CC6C34
P2860
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@en
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@nl
type
label
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@en
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@nl
prefLabel
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@en
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@nl
P2093
P2860
P356
P1433
P1476
Interference with PD-L1/PD-1 c ...... y of antigen-specific T cells.
@en
P2093
B D Keersmaecker
J Corthals
K Thielemans
T Liechtenstein
P2860
P2888
P304
P356
10.1038/GT.2013.80
P577
2014-01-09T00:00:00Z
P5875
P6179
1017529500